Matrix Metalloproteinase Inhibitors
"Matrix Metalloproteinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES.
| Descriptor ID |
D061965
|
| MeSH Number(s) |
D27.505.519.389.745.610
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Matrix Metalloproteinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Matrix Metalloproteinase Inhibitors".
This graph shows the total number of publications written about "Matrix Metalloproteinase Inhibitors" by people in this website by year, and whether "Matrix Metalloproteinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2010 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Matrix Metalloproteinase Inhibitors" by people in Profiles.
-
MMP-8 Is Critical for Dexamethasone Therapy in Alkali-Burned Corneas Under Dry Eye Conditions. J Cell Physiol. 2016 11; 231(11):2506-16.
-
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res. 2010; 12(6):R96.
-
The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidase [correction of oxidas], ETA, ETB, and MMP9 in the vasculature. J Cardiovasc Pharmacol. 2008 Jul; 52(1):42-8.
-
ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Res. 2007 Jun 01; 67(11):5258-66.
-
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther. 2006 Nov; 5(11):2685-95.
-
Hypoxia suppresses the production of matrix metalloproteinases and the migration of human monocyte-derived dendritic cells. Eur J Immunol. 2005 Dec; 35(12):3468-77.
-
Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model. Cancer Lett. 2006 Jul 18; 238(2):197-201.
-
Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004 Dec; 45(12):4302-11.
-
An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ. 2003 May; 10(5):558-69.
-
Purification and characterization of catalytic domains of gelatinase A with or without fibronectin insert for high-throughput inhibitor screening. Protein Expr Purif. 2003 Jan; 27(1):63-74.